T. Rowe Price Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10,869
| Closed | -$18K | – | 3084 |
|
|
2024
Q1 | $18K | Buy |
10,869
+783
| +8% | +$1.3K | ﹤0.01% | 2932 |
|
|
2023
Q4 | $9K | Sell |
10,086
-34,200
| -77% | -$30.5K | ﹤0.01% | 2889 |
|
|
2023
Q3 | $48K | Sell |
44,286
-2,677
| -6% | -$2.9K | ﹤0.01% | 2782 |
|
|
2023
Q2 | $122K | Hold |
46,963
| – | – | ﹤0.01% | 2655 |
|
|
2023
Q1 | $192K | Buy |
46,963
+6,776
| +17% | +$27.7K | ﹤0.01% | 2544 |
|
|
2022
Q4 | $202K | Buy |
40,187
+6,242
| +18% | +$31.4K | ﹤0.01% | 2529 |
|
|
2022
Q3 | $445K | Buy |
33,945
+13,505
| +66% | +$177K | ﹤0.01% | 2173 |
|
|
2022
Q2 | $262K | Buy |
20,440
+1,425
| +7% | +$18.3K | ﹤0.01% | 2492 |
|
|
2022
Q1 | $290K | Buy |
19,015
+795
| +4% | +$12.1K | ﹤0.01% | 2552 |
|
|
2021
Q4 | $323K | Sell |
18,220
-366,496
| -95% | -$6.5M | ﹤0.01% | 2572 |
|
|
2021
Q3 | $8.09M | Sell |
384,716
-49,142
| -11% | -$1.03M | ﹤0.01% | 1446 |
|
|
2021
Q2 | $8.56M | Buy |
433,858
+54,395
| +14% | +$1.07M | ﹤0.01% | 1433 |
|
|
2021
Q1 | $11M | Buy |
+379,463
| New | +$11M | ﹤0.01% | 1380 |
|